Cargando…

Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study

BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long‐term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers w...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Malcolm, Kirby, Adrienne, Stewart, Ralph A., Blankenberg, Stefan, Sullivan, David, White, Harvey D., Hunt, David, Marschner, Ian, Janus, Edward, Kritharides, Leonard, Watts, Gerald F., Simes, John, Tonkin, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075058/
https://www.ncbi.nlm.nih.gov/pubmed/35179040
http://dx.doi.org/10.1161/JAHA.121.020745
_version_ 1784701596453568512
author West, Malcolm
Kirby, Adrienne
Stewart, Ralph A.
Blankenberg, Stefan
Sullivan, David
White, Harvey D.
Hunt, David
Marschner, Ian
Janus, Edward
Kritharides, Leonard
Watts, Gerald F.
Simes, John
Tonkin, Andrew M.
author_facet West, Malcolm
Kirby, Adrienne
Stewart, Ralph A.
Blankenberg, Stefan
Sullivan, David
White, Harvey D.
Hunt, David
Marschner, Ian
Janus, Edward
Kritharides, Leonard
Watts, Gerald F.
Simes, John
Tonkin, Andrew M.
author_sort West, Malcolm
collection PubMed
description BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long‐term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long‐Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow‐up, 6 years) and long‐term (median follow‐up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR‐creatinine, then GFR‐creatinine‐cystatin C). Over 6 years, in fully adjusted multivariable time‐to‐event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07–1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19–1.82; P<0.001). Over 16 years, the association of baseline cystatin C with coronary heart disease, cardiovascular, and all‐cause mortality persisted (each P<0.001) and remained significant after adjustment for estimated GFR‐creatinine‐cystatin C. Cystatin C also predicted the development of chronic kidney disease for 6 years (odds ratio, 6.61; 95% CI, 4.28–10.20) independently of estimated GFR‐creatinine and other risk factors. However, this association was no longer significant after adjustment for estimated GFR‐creatinine‐cystatin C. CONCLUSIONS: Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all‐cause mortality. Prediction of long‐term mortality was independent of improved estimation of GFR. REGISTRATION: URL: https://anzctr.org.au; Unique identifier: ACTRN12616000535471.
format Online
Article
Text
id pubmed-9075058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90750582022-05-10 Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study West, Malcolm Kirby, Adrienne Stewart, Ralph A. Blankenberg, Stefan Sullivan, David White, Harvey D. Hunt, David Marschner, Ian Janus, Edward Kritharides, Leonard Watts, Gerald F. Simes, John Tonkin, Andrew M. J Am Heart Assoc Original Research BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long‐term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long‐Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow‐up, 6 years) and long‐term (median follow‐up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR‐creatinine, then GFR‐creatinine‐cystatin C). Over 6 years, in fully adjusted multivariable time‐to‐event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07–1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19–1.82; P<0.001). Over 16 years, the association of baseline cystatin C with coronary heart disease, cardiovascular, and all‐cause mortality persisted (each P<0.001) and remained significant after adjustment for estimated GFR‐creatinine‐cystatin C. Cystatin C also predicted the development of chronic kidney disease for 6 years (odds ratio, 6.61; 95% CI, 4.28–10.20) independently of estimated GFR‐creatinine and other risk factors. However, this association was no longer significant after adjustment for estimated GFR‐creatinine‐cystatin C. CONCLUSIONS: Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all‐cause mortality. Prediction of long‐term mortality was independent of improved estimation of GFR. REGISTRATION: URL: https://anzctr.org.au; Unique identifier: ACTRN12616000535471. John Wiley and Sons Inc. 2022-02-18 /pmc/articles/PMC9075058/ /pubmed/35179040 http://dx.doi.org/10.1161/JAHA.121.020745 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
West, Malcolm
Kirby, Adrienne
Stewart, Ralph A.
Blankenberg, Stefan
Sullivan, David
White, Harvey D.
Hunt, David
Marschner, Ian
Janus, Edward
Kritharides, Leonard
Watts, Gerald F.
Simes, John
Tonkin, Andrew M.
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
title Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
title_full Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
title_fullStr Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
title_full_unstemmed Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
title_short Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
title_sort circulating cystatin c is an independent risk marker for cardiovascular outcomes, development of renal impairment, and long‐term mortality in patients with stable coronary heart disease: the lipid study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075058/
https://www.ncbi.nlm.nih.gov/pubmed/35179040
http://dx.doi.org/10.1161/JAHA.121.020745
work_keys_str_mv AT westmalcolm circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT kirbyadrienne circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT stewartralpha circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT blankenbergstefan circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT sullivandavid circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT whiteharveyd circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT huntdavid circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT marschnerian circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT janusedward circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT kritharidesleonard circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT wattsgeraldf circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT simesjohn circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT tonkinandrewm circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy
AT circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy